Fig. 4 | Scientific Reports

Fig. 4

From: VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma

Fig. 4

Potential of VS-4718 to enhance the effects of carf in parental and resistant HMCLs. (A) L-363 and L363R350Ixa cells were treated with 3 µM VS-4718 and 3 nM carf, or (B) 6 nM carf. (C) MM.1 S and MM1.SR180Ixa cells were treated with 3 µM VS-4718 and 1 nM carf, (D) 1.5 nM carf, and (E) 2 nM carf. Survival was determined by Annexin V-647/PI staining and subsequent measurements were performed with a BD FACS Canto II from BD Biosciences. Bars represent the mean ± SD of three independent experiments. P-values were determined in a two-way ANOVA using Geisser-Greenhouse correction and a Tukey’s multiple comparison test and only depicted for p < 0.05. To focus on the most relevant findings, the depiction of statistical comparisons was limited to comparisons of single drugs vs. drug combinations and parental vs. PI-resistant cell lines.

Back to article page